A Notable Impact of Rituximab in Managing Follicular Lymphoma: A Case Report and Review of Management Strategies

Abstract

Aim: This case report emphasises the hope for distressed patients with follicular lymphoma, highlighting the impact of rituximab-based immunochemotherapy on the prognosis and quality of life of a patient treated at Redeemers Health Village, a multi-specialty tertiary academic hospital located in the Southwestern region of Nigeria while also reviewing the management strategies. Presentation of Case: This report describes the case of a 45-year-old Uber driver diagnosed with stage IVB high-risk follicular lymphoma (FL). The patient’s Follicular Lymphoma International Prognostic Index (FLIPI) score of 4 was based on his elevated Lactate Dehydrogenase levels, Ann Arbor stage IV, over four (4) lymph node areas involvement, haemoglobin concentration value of < 12g/dL, and age <60. The patient underwent a complete treatment course of rituximab combined with chemotherapy. This treatment resulted in significant clinical improvement from carrying a high tumour burden to full active health. Discussion: Until recently, the treatment for FL has been quite challenging.  The three-year event-free survival (EFS) and overall survival (OS) rates with Cyclophosphamide. Hydroxyrubicin, Oncovin, and Prednisolone (CHOP) regimen were previously as low as 30% and 35% to 40%, respectively. However, the outlook significantly improved after the introduction and approval of rituximab for use alongside CHOP in 1997 and 2006, resulting in EFS and OS rates 95% and 70% respectively. Although rituximab-based therapy has only recently become widely available, its inclusion in routine treatment regimens has provided renewed hope and improved overall survival for our patients. Similarly, while exploring other anti-CD20 targeted therapies, Obinutuzumab has emerged as an effective alternative monoclonal antibody that shows promise. In those with transformed FL (DLBCL), relapsed or refractory FL (grade 1 to 3A), innovative therapies, such as bispecific T-cell engager (BiTE) therapy (e.g., Mosunetuzumab and Glofitamab), and chimeric antigen receptor T-cell therapy (e.g., Tisagenlecleucel, and Axicabtagene ciloleucel), are expected to enhance patients’ outlooks, and provided reassurance that regaining a pre-morbid state of health is possible. Conclusion: Managing non-Hodgkin lymphoma (NHL), including follicular lymphoma, has historically posed significant challenges. The availability of rituximab has notably improved treatment outcomes for NHL overall. Exploring other anti-CD 20 alternatives such as Obinutuzumab, along with innovative therapies like bispecific T-cell engager (BiTE) therapy and chimeric antigen receptor T-cell (CAR T-cell) therapy, will further enhance the prospects for these patients. The possibility of regaining their pre-morbid state of health is increasingly reassuring.